AstraZeneca PLC (NASDAQ: AZN) announced it has received marketing clearance from China’s National Medical Products Administration (NMPA) for Fasenra (benralizumab) as a treatment for hypereosinophilic syndrome (HES) in patients aged 12 years and older without identifiable non-hematologic secondary causes. This approval establishes Fasenra as the first and only biologic therapy approved for HES in China.
Regulatory Milestone & Indication Expansion
Parameter
Detail
Regulatory Agency
NMPA (China)
Approval Type
Marketing authorization
New Indication
Hypereosinophilic syndrome (HES) in patients ≥12 years
Significance
First and only biologic approved for HES in China
Previous China Approvals:
• Severe eosinophilic asthma (SEA) – adults/adolescents ≥12 years
August 2024
• Pediatric SEA – patients ≥6 years
August 2025
• Eosinophilic granulomatosis with polyangiitis (EGPA) – adults
December 2025
Drug Profile & Mechanism of Action
Drug Class: Anti-IL-5 receptor alpha (IL-5Rα) monoclonal antibody
Target: Eosinophils (key drivers of HES pathology)
Mechanism: Directly depletes eosinophils through antibody-dependent cellular cytotoxicity (ADCC)
Dosing Advantage: Subcutaneous administration with extended dosing intervals
Therapeutic Rationale: Addresses root cause of HES by eliminating pathogenic eosinophils
Strategic Partnership & Development History
Benralizumab Rights Evolution
Date
Transaction
Parties Involved
Rights Transferred
October 2016
Initial partnership
AstraZeneca/Kyowa Kirin
Global commercialization rights (excluding Japan)
March 2019
Asia expansion
AstraZeneca/Kyowa Kirin
Development and commercialization rights in Asia
December 2026
US/Europe rights
Kyowa Kirin/MedImmune
Commercialization rights for US, Europe and others
April 2027
Acquisition
AstraZeneca acquires MedImmune
$15.6 billion deal securing benralizumab and pipeline
Franchise Expansion: Third indication in China builds on established eosinophil-targeting platform
Physician Leverage: Existing relationships with pulmonologists and rheumatologists facilitate HES adoption
Pricing Premium: First-mover biologic status supports premium pricing in orphan indication
Diagnostic Partnerships: Likely collaboration with laboratories for HES diagnosis and eosinophil monitoring
China Rare Disease Market Dynamics
Policy Support: Government initiatives to accelerate orphan drug approvals
Reimbursement Pathway: Orphan designation may support favorable NRDL inclusion negotiations
Healthcare Infrastructure: Growing number of specialized centers capable of managing complex eosinophilic disorders
Patient Advocacy: Emerging patient organizations driving awareness and treatment access
Implementation Timeline & Commercial Outlook
Market Launch: Expected Q3 2026
Target Specialists: Hematologists, immunologists, and specialized internal medicine physicians
Education Campaign: Focus on HES diagnosis criteria and treatment guidelines
Revenue Potential: Estimated ¥300-500 million annual peak sales in Chinese HES market
Forward-Looking Statements This brief contains forward-looking statements regarding market launch, commercial performance, and regulatory compliance for Fasenra (benralizumab). Actual results may differ due to risks including market competition, pricing negotiations, healthcare policy changes, and evolving diagnostic and treatment guidelines for hypereosinophilic syndrome.-Fineline Info & Tech
By Fineline Cube 